Beta Bionics (NASDAQ:BBNX) Earns Overweight Rating from Analysts at Piper Sandler

Piper Sandler began coverage on shares of Beta Bionics (NASDAQ:BBNX) in a research note released on Monday morning, MarketBeat.com reports. The brokerage issued an overweight rating and a $26.00 target price on the stock.

Other equities analysts have also recently issued reports about the stock. Robert W. Baird started coverage on shares of Beta Bionics in a research report on Thursday, February 20th. They set a “neutral” rating and a $20.00 price objective for the company. Baird R W raised shares of Beta Bionics to a “hold” rating in a report on Thursday, February 20th. LADENBURG THALM/SH SH began coverage on shares of Beta Bionics in a report on Thursday, February 20th. They issued a “neutral” rating and a $20.00 price target on the stock. Finally, Leerink Partners began coverage on Beta Bionics in a report on Monday. They set an “outperform” rating and a $28.00 price objective for the company. Three analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $24.83.

Beta Bionics Trading Up 4.3 %

Shares of NASDAQ BBNX opened at $19.99 on Monday. Beta Bionics has a 12 month low of $18.67 and a 12 month high of $24.50.

Insiders Place Their Bets

In related news, major shareholder Hadley Harbor Aggre Wellington acquired 1,000,000 shares of the stock in a transaction on Friday, January 31st. The shares were purchased at an average price of $17.00 per share, for a total transaction of $17,000,000.00. Following the purchase, the insider now directly owns 3,901,599 shares in the company, valued at approximately $66,327,183. The trade was a 34.46 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Mike Mensinger acquired 33,350 shares of the company’s stock in a transaction on Friday, January 31st. The stock was bought at an average cost of $17.00 per share, with a total value of $566,950.00. Following the completion of the acquisition, the insider now directly owns 59,019 shares in the company, valued at approximately $1,003,323. This represents a 129.92 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.